Hi-Tech Pharmacal of Amityville announces 1Q profit
Hi-Tech Pharmacal, Amityville
Pharmaceutical maker
Third Quarter: Ended Jan. 31
Net income: Profit of $8.5 million, compared with profit of $2.1 million in the same quarter last year.
Net sales: $38.8 million compared with $29.4 million in the year-ago quarter.
Outlook: Hi-Tech has 15 brand-name and generic products awaiting federal approval, with sales targets of $600 million. The company also has 20 products in active development targeting brand sales of more than $2 billion.
Company statement: A "diversified base of success across multiple product lines and businesses demonstrates the company's ability to execute in multiple markets," David Seltzer, president and chief executive, said in a news release.
Spotted lanternflies on the rise The plant-eating pests are raising concerns among farmers and winemakers. Newsday reporter Mark Harrington spoke about some potential upcoming solutions.
Spotted lanternflies on the rise The plant-eating pests are raising concerns among farmers and winemakers. Newsday reporter Mark Harrington spoke about some potential upcoming solutions.
